Last Updated: October 3, 2025
Analyzing Management
Leadership at public companies plays a crucial role in both the early due diligence and continuous risk assessment processes for hedge funds and asset managers. ManagementTrack offers a consistent approach that eliminates distractions by highlighting distinct strengths and weaknesses, identifying warning signs and positive indicators, and establishing a straightforward connection between CEO actions and investment outcomes.
CEO Leach’s manufacturing woes may threaten the G7 launch and margin recovery
Analysis of DexCom CEO Jake Leach
Despite some product vision, a record of manufacturing failures and recalls may leave the CEO poorly aligned to execute the critical G7 launch and margin recovery that DexCom currently requires.
Management evaluated Jake Leach’s track record and skillset against the following key factors for DXCM:
- Commercial Launch and Adoption of the 15-Day G7 Sensor.
- Gross Margin Recovery and Supply Chain Normalization.
- Navigating Intensifying Competition with Abbott.
- Penetrating the Type 2 Non-Insulin Market via Stelo and Expanded Reimbursement.
Jake Leach’s Track Record & Key Open Questions to Research
ManagementTrack provides track record analysis, career playbooks, strengths, and weaknesses for every CEO. It allows investors to dig deeper to uncover hard to find data to answer the most pressing questions.
Reach out to sales@paragonintel.com or visit https://paragonintel.com/access-now/ for more information.
Question #1
Given the tension between his track record as a product innovator and recent major operational failures, will Leach prioritize launching the next product to outpace competitors or will he delay future innovations to personally lead the difficult, systemic overhaul of DexCom’s manufacturing and quality control?
Question #2
When confronted with a significant internal failure, such as the G7 quality issues or the FDA warning letter, does Leach’s playbook favor transparently addressing the root cause with the team and the public, or does he default to managing the external narrative to minimize perceived damage?
Question #3
As intensifying competition from Abbott exploits the very quality and reliability issues that have occurred on his watch, is Leach’s instinct to double down on a premium-product strategy that may no longer be defensible, or does he have the commercial and strategic agility to pivot the company’s competitive approach?
Why Do Investors Use ManagementTrack?
Q: What is ManagementTrack’s analysis of Jake Leach at DXCM?
A: ManagementTrack’s assessment is built on its proprietary career analysis and interviews with former colleagues to establish a track record, core strengths, and key weaknesses. This profile is then measured against DXCM’s most critical challenges: executing the commercial launch of the G7 sensor, recovering gross margins through supply chain normalization, navigating intensifying competition with Abbott, and penetrating the non-insulin Type 2 market.
Q: How else does ManagementTrack connect executive behavior to future company performance?
A: Proprietary ManagementTrack models are utilized to detect executive evasion in earnings call Q&A and ascertain if the behavior is abnormal. The platform also examines every insider transaction to isolate outliers that can forecast future stock outperformance or underperformance. When synthesized with the ManagementTrack Rating, a 1-10 predictive score assigned to each executive, these tools offer investors a clear, actionable view on management’s probable impact on future performance.
Q: What is the scope of ManagementTrack’s coverage?
A: ManagementTrack provides real-time coverage of the executive suite at every publicly traded company.
How to Learn More
Reach out to sales@paragonintel.com or visit https://paragonintel.com/access-now/ to see our deep dive analysis on any executive.
Author
Author. Colby Howard is the co-founder and President of Paragon Intel. Paragon Intel’s ManagementTrack is the premier executive analysis platform for hedge funds, asset managers, corporations, boards, and recruiters. Our proprietary data, built over a decade of analysis, allows us to analyze each public company executive to understand their fit and ability to execute at their company. We leverage our proprietary data – key quantitative research on an executive’s career plus interviews with their former colleagues – with public documents, including SEC filings (10-K, 10-Q), investor presentations, press releases, and earnings call transcripts. to build a holistic, evidence-based view of an executive’s capabilities and playbook.
Sources
- Verified Career History by ManagementTrack for Jake Leach
- Analysis of Capital Allocation, Performance, and Fundamentals across career by ManagementTrack
- DexCom, Inc. 10Q
- DexCom, Inc. 10K
- DexCom, Inc. Earnings Calls
- DexCom, Inc. Press Releases
Relevant Links
- For more information on ManagementTrack’s Data visit: https://paragonintel.com/management-track-data/
- For more information on ManagementTrack’s Interview & Analysis visit: https://paragonintel.com/management-track-reports/
- For more information on ManagementTrack’s Interview library visit: https://paragonintel.com/management-track-report-library/
- For more information on ManagementTrack’s Evasion Analysis visit: https://paragonintel.com/earnings-call-evasion/
- For more information on how ManagementTrack helps hedge funds and asset managers visit: https://paragonintel.com/
